Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2020 Oct 16;99(2):115242. doi: 10.1016/j.diagmicrobio.2020.115242

A comprehensive and contemporary “snapshot” of β-lactamases in carbapenem resistant Acinetobacter baumannii

Andrea M Hujer a,b, Kristine M Hujer a,b, David A Leonard c, Rachel A Powers c, Bradley J Wallar c, Andrew R Mack b,d, Magdalena A Taracila a,b, Philip N Rather e,f,g, Paul G Higgins h,i, Fabio Prati j, Emilia Caselli j, Steven H Marshall b, Thomas Clarke k, Christopher Greco k, Pratap Venepally k, Lauren Brinkac l, Barry N Kreiswirth m, Derrick E Fouts k, Robert A Bonomo a,b,d,n,o,⁎; for the Antibacterial Resistance Leadership Group (ARLG)
PMCID: PMC7562987  PMID: 33248392

Abstract

Successful treatment of Acinetobacter baumannii infections require early and appropriate antimicrobial therapy. One of the first steps in this process is understanding which β-lactamase (bla) alleles are present and in what combinations. Thus, we performed WGS on 98 carbapenem-resistant A. baumannii (CR Ab). In most isolates, an acquired blaOXA carbapenemase was found in addition to the intrinsic blaOXA allele. The most commonly found allele was blaOXA-23 (n = 78/98). In some isolates, blaOXA-23 was found in addition to other carbapenemase alleles: blaOXA-82 (n = 12/78), blaOXA-72 (n = 2/78) and blaOXA-24/40 (n = 1/78). Surprisingly, 20% of isolates carried carbapenemases not routinely assayed for by rapid molecular diagnostic platforms, i.e., blaOXA-82 and blaOXA-172; all had ISAba1 elements. In 8 CR Ab, blaOXA-82 or blaOXA-172 was the only carbapenemase. Both blaOXA-24/40 and its variant blaOXA-72 were each found in 6/98 isolates. The most prevalent ADC variants were blaADC-30 (21%), blaADC-162 (21%), and blaADC-212 (26%). Complete combinations are reported.

Keywords: ADC β-lactamase, Carbapenem resistant Acinetobacter baumannii, OXA-172, OXA-82, OXA-23, OXA carbapenemase

1. Introduction

Multidrug-resistant (MDR) Acinetobacter baumannii (Ab) pose a significant challenge to modern medicine. The World Health Organization categorizes MDR Ab as the “highest priority pathogen” for which antibiotic development is urgently needed (Who-Publishes-List, 2020), and studies that aid our understanding of this organism are certain to have significant impact on this crisis. Currently, very few therapeutic agents exist or are in development that can be used to treat MDR Ab infections, including those of the bloodstream. In efforts to address this persistent dilemma, multiple pharmaceutical companies have undertaken different approaches to enhance our current therapeutic arsenal. These efforts include the development of a novel fluorocycline (eravacycline), siderophore β-lactams (e.g., cefiderocol), and more effective β-lactam β-lactamase inhibitors (e.g., sulbactam/ETX2514 and cefepime/WCK4234) (Choi and McCarthy, 2018; Durand-Reville et al., 2017; Ito et al., 2018; Mushtaq et al., 2017; Papp-Wallace et al., 2018; Shapiro et al., 2017; Zhanel et al., 2016). In studies performed to date, these therapeutics are showing significant promise, but the fear is ever present that even these will fall short as universal agents to reliably treat MDR Ab.

β-lactamase inhibition is key in preserving efficacy of our current armamentarium of antibiotics against Ab. However, many times the focus of that inhibition is on a single class of β-lactamase. Clearly, in inhibitor design, we need to take into account all β-lactamases occurring in an individual organism, based upon our understanding of currently circulating alleles in isolates. In addition to OXA carbapenemases that Ab can acquire (e.g., OXA-23 [originally called ARI-1] and OXA-24/40), they possess an intrinsic OXA and AmpC (Acinetobacter Derived Cephalosporinase, ADC) β-lactamase, that can confer resistance to carbapenems and cephalosporins, respectively (Bou et al., 2000; Donald et al., 2000; Hujer et al., 2005). Therefore, class C and D β-lactamases are important targets for intervention as they are the major contributors of β-lactam resistance in Ab.

With these goals in mind, we performed whole genome sequencing (WGS) on 98 carbapenem-resistant Ab isolates (CR Ab, resistant to doripenem, imipenem, and meropenem) (Evans et al., 2017) and assessed the various β-lactamase combinations contained therein. This WGS database, and others like it, will be important in providing context to future work in the area of β-lactamase inhibitor design and provides a comprehensive “snapshot” of recently circulating β-lactamase genes (bla genes) in CR Ab. A better understanding of how to treat infections caused by opportunistic organisms like Ab will potentially be crucial in the fight for patients in the ICU on ventilators that are at an increased risk of hospital-acquired and ventilator-associated pneumonia caused by CR Ab. As CR Ab is a leading cause of hospital-acquired pneumonia, and also reported to be a pathogen of community-acquired Gram-negative pneumonia (Chung et al., 2011; Cilloniz et al., 2019; Lescure et al., 2020; Mohd Sazlly Lim et al., 2019; Ozgur et al., 2014; Serota et al., 2018; Wong et al., 2017). This could be especially significant during the COVID-19 pandemic (Lescure et al., 2020).

2. Methods and materials

This group of isolates was used in the Primers III study and a description of the isolates can be found there (Evans et al., 2017; Hujer et al., 2006; Perez et al., 2010). In short, the isolates used in this study consisted of 94 carbapenem resistant Ab collected between 2007 and 2013 from a 6-hospital healthcare system in Northeast Ohio: including 5 community hospitals and a facility serving as both as a long-term care unit and a long-term acute care hospital. Four additional Ab were collected from patients at the Walter Reed Army Medical Center between March 2003 and February 2005. All Ab clinical isolates in this study displayed an MDR phenotype and were resistant to all carbapenems tested.

The genomes of all Ab clinical isolates were sequenced using paired-end NexteraXT libraries by Illumina NextSeq (2 × 150 bp) to ∼100-fold coverage. Reads were assembled using SPAdes (Bankevich et al., 2012), annotated using NCBI's Prokaryotic Genome Annotation Pipeline (Tatusova et al., 2016) and deposited in the NCBI SRA and GenBank WGS repositories (BioProjects PRJNA384060 and PRJNA384065). In addition, the DNA sequence for each isolate was analyzed using ResFinder at the Center for Genomic Epidemiology website. β-lactamase genes were manually extracted if not a 100% match with 100% coverage of a known β-lactamase gene.

For PCR analysis of ISAba1 upstream of bla OXA-82 and bla OXA-172, the following primer set was used: 5’ TGGATTGCACTTCATCTTGG 3’ (OXA-51) and 5’ CACGAATGCAGAAGTTG 3’ (ISAba1) (Segal et al., 2005; Woodford et al., 2006). This combination of primers produces an approximate 1200 bp product when ISAba1 is proximal to the bla OXAs.

3. Results

From the WGS data, the combination of β-lactamases found in each isolate was determined, along with the Pasteur and Oxford Multilocus Sequence Types (Bartual et al., 2005; Diancourt et al., 2010). This was done for each of the 98 CR Ab. The predominant Pasteur sequence type was the ST2 group, which is also known as international clonal lineage 2 (IC2). There were 79 CR Ab that were ST2, and 19 that were non-ST2 according to the Pasteur Scheme. Using the Oxford scheme ST1626 and ST1631 accounted for 40 and 23 isolates, respectively. Table 1 summarizes the combination of β-lactamases found in this collection, as well as which STs they were found in.

Table 1.

β-lactamase combinations found within the 98 carbapenem resistant Acinetobacter baumannii.

All β-lactamases present
Pasteur ST - (# of Isolates) Carbapenemase Intrinsic OXA ADC Other Oxford ST
ST2 - (21) OXA-23 OXA-66 ADC-212 ST1631
ST2 - (16) OXA-23 OXA-66 ADC-162 TEM-1 ST1626 - (13), ST1660 - (1), ST1661 - (1), ST1676 - (1)
ST2 - (9) OXA-23 OXA-66 ADC-30 TEM-1 ST1626
ST2 - (5) OXA-23 OXA-66 ADC-162 ST1626
ST2 - (1) OXA-23 OXA-66 ADC-143 TEM-1 ST1626
ST2 - (1) OXA-23 OXA-66 ADC-213 ST1631
ST2 - (1) OXA-23 OXA-66 ADC-30 ST1626
ST2 - (3) OXA-23, OXA-82a ADC-56 TEM-1 ST1626
ST2 - (3) OXA-23, OXA-82a ADC-33 ST1637
ST2 - (3) OXA-23, OXA-82a ADC-219 ST1637
ST2 - (3) OXA-23, OXA-82a ADC-30 ST1626
ST2 - (1) OXA-82a ADC-56 ST1626
ST2 - (1) OXA-82a ADC-219 ST1637
ST2 - (2) OXA-82a ADC-30 ST1626
ST2 - (1) OXA-82a ADC-33 ST1637
ST2 - (1) OXA-23c, OXA-82a ADC-212 ST1631
ST2 - (3) OXA-72 OXA-66 ADC-30 ST1626 - (1), ST1628 - (2)
ST2 -(1) OXA-72c OXA-66 ADC-217 ST1628
ST2 - (2) OXA-23, OXA-72 OXA-66 ADC-30 ST1628 - (1), ST1632 - (1)
ST2 - (1) OXA-58 OXA-66 ADC-30 TEM-1 ST1626
ST250 - (3) OXA-23 OXA-407 ADC-216 ST1646
ST10 - (2) OXA-23 OXA-68 ADC-76 ST447
ST406 - (2) OXA-23 OXA-71 ADC-212 ST1635
ST1 - (1) OXA-23 OXA-69 ADC-176c TEM-1 ST1663
ST25 - (1) OXA-23 OXA-64 ADC-26 ST993
ST79 - (1) OXA-23, OXA-24/40 OXA-65 ADC-218 ST1629
ST79 - (1), ST93 - (1) OXA-24/40 OXA-65 TEM-1 ST1348 - (1), ST1629 - (1)
ST79 - (1) OXA-24/40 OXA-65 ADC-218 ST1629
ST406 - (1) OXA-24/40 OXA-71 ADC-212 ST1635
ST79 - (1) OXA-24/40 OXA-65 ADC-214 TEM-1 ST1629
ST32 - (1) OXA-58 OXA-100 ADC-79 ST1627
ST406 - (1) OXA-72 OXA-223 ADC-220 ST1635
ST1088 - (2) OXA-172b ADC-215 ST1656 (1), ST1669 (1)
Open in a new tab
a

OXA-82 is a single amino acid variant of the intrinsic OXA-66 with carbapenemase activity.

b

OXA-172 is a double amino acid variant of OXA-66 with carbapenemase activity.

c

Partial sequence.

3.1. blaOXAs

In most isolates, an acquired bla OXA carbapenemase was found in addition to the intrinsic or chromosomal bla OXA allele. However, in 18 ST2 isolates, the intrinsic bla OXA acquired a single point mutation that converted bla OXA-66 (the variant associated with IC2 isolates) to bla OXA-82 (Table 1) (Zander et al., 2013). bla OXA-82 was also found as the sole carbapenemase allele in 6% of isolates. In addition, bla OXA-172 was found in two ST1088 isolates. Both OXA-82 (OXA-66 variant with L167V), and OXA-172 (OXA-66 variant with I129V and W222L) are carbapenemases (Mitchell and Leonard, 2014; Schroder et al., 2016; Zander et al., 2013), and were found in combination with ISAba1 upstream of the bla OXA gene as evidenced by PCR analysis.

By far, the most commonly found acquired OXA carbapenemase allele was bla OXA-23 (Table 1) (Donald et al., 2000). This bla gene was detected in 78 of the 98 CR isolates. In 81% (n = 63/78) of the isolates containing bla OXA-23, it was the only carbapenemase present. However, in some isolates it was found in addition to other carbapenemase alleles, i.e., in addition to bla OXA-82 (n = 12/78), bla OXA-72 (n = 2/78) and bla OXA-24/40 (n = 1/78). The carbapenemase genes bla OXA-24/40 (Bou et al., 2000) and its variant bla OXA-72 were each found in 6/98 isolates (both alone and in combination with bla OXA-23), but never found together in a single isolate (Table 1). While the bla OXA-58 allele (Poirel et al., 2005) was found in 2 isolates as the sole carbapenemase gene.

3.2. blaADCs

The most prevalent Acinetobacter Derived Cephalosporinase (ADC) variants were bla ADC-30 (n = 21/98 isolates), bla ADC-162 (ADC-30 variant with an A220E mutation in the Ω loop, n = 21/98), and bla ADC-212 (ADC-25 variant with A200D, P219L, and an alanine insertion in the Ω loop, n = 25/98; Tables 1 and 2 ) (Kuo et al., 2015). Also, of note, bla ADC-33 and bla ADC-219 (ADC-33 with G222D) were found in 8/98 isolates (Rodriguez-Martinez et al., 2010). Other ADC variants (21/98) were found in all but 2 isolates (Table 1). Numbering of the amino acids in the ADC variants is based on the SANC numbering scheme (Mack et al., 2019).

Table 2.

New ADC variants in this study.

New ADC number ADC-like Reference number
ADC-212 ADC-25 A200D, P219L, Ala219a ins btw P219L and A220 OTN05897.1
ADC-213 ADC-25 A200D, ins of SLA that replaces AP btw D217 and A220 OTR53589.1
ADC-214 ADC-52 G222S, N320T OTR85897.1
ADC-215 ADC-170 G214A, P219S, S320T OTT53070.1
ADC-216 ADC-25 G75A, D86N, S143P, P169S, N206K, T279P OTT57830.1
ADC-217 ADC-30 V262E OTT60833.1
ADC-218 ADC-30 A200D, P219L, Ala219a ins btw P219L and A220, K362E OTU52329.1
ADC-219 ADC-33 G222D OTU79690.1
ADC-220 ADC-25 Q120K, A200D, P219L OVN99777.1
Open in a new tab

Many combinations of β-lactamases were found in individual isolates. However, certain combinations were more frequent than others. The 3 most frequently found combinations were: OXA-23/OXA-66/ADC-162 with or without TEM-1 (n = 21); OXA-23/OXA-66/ADC-212 (n = 21); and OXA-23/OXA-66/ADC-30 with or without TEM-1 (n = 10) (Table 1). The high prevalence of OXA-66 reflects the prevalence of ST2 isolates circulating in hospitals (Adams et al., 2019; Wright et al., 2014; Wright et al., 2016).

4. Discussion

The current prevalence of multidrug- and pandrug-resistant strains of Ab, combined with the lack of new antibiotics, underscores the critical need for the development of novel therapeutic strategies to combat this pathogen. The end goal of studies like this is to facilitate the design of inhibitors that target the most prevalent combinations of β-lactamases occurring in circulating CR Ab, and the first step in this process is to determine which β-lactamase alleles are present in contemporary isolates.

Building upon our work with PRIMERS III, an evaluation of rapid molecular diagnostics to identify carbapenem susceptibility and resistance in Acinetobacter spp. (Evans et al., 2017), our group performed an extensive analysis of the WGS of 98 CR Ab strains used in that study, with particular attention being paid to the β-lactamase combinations contained within each isolate. Based on these results: Table 1 summarizes β-lactamase alleles present; Table 2 describes the new ADCs in this collection, Table 3 presents what is already known about the key properties and structure/function basis of the OXA carbapenemases and ADC β-lactamases found herein, and Table 4 compares the ability of various rapid molecular diagnostic (RMD) platforms to detect the carbapenemases found in this collection, as determined from the platform's product literature.

Table 3.

Class C and D β-lactamases most prevalent in the clinical isolates of carbapenem-resistant A. baumannii.

β-lactamase Variant Property Structure/function rationale Ref.
Class D carbapenemases OXA-23 and OXA-24/40 High-affinity carbapenemases Similar bridge residues in OXA-24/40 (Y112 and M223) and OXA-23 (F110 and M221) suggest that both use the same mechanism to achieve tight substrate binding in order to compensate for a slow turnover rate of carbapenems, thus resulting in clinical resistance. Structural analyses of OXA-24/40, with and without doripenem bound, revealed that the hydrophobic bridge across the top of the active site helps hold onto carbapenems that possess extended nonpolar side chains. However, penicillins that possess bulky side chains are sterically prohibited in the active site. Kaitany et al. (2013), Santillana et al. (2007), Schneider et al. (2011), Smith et al. (2013), Stewart et al. (2019)
OXA-72 High-affinity carbapenemase OXA-24/40 with G224D substitution in the β5β6 loop causes no loss of activity for carbapenems. A crucial role of the β5-β6 loop in carbapenemase activity of class D β-lactamases has been demonstrated. Schneider et al. (2011), Lu et al. (2009), De Luca et al. (2011)
OXA-82 Carbapenem gain-of-function As demonstrated with molecular modeling, OXA 51/66 with a L167V substitution makes room for the rotation of the side-chain of I129; this in turn removes the steric clash of isoleucine with the hydroxyethyl group of carbapenems and affinity is greatly increased. Zander et al. (2013), Mitchell and Leonard (2014)
OXA-172 Carbapenem gain-of-function Substitutions, I129V and W222L in OXA-66. Result in tighter binding of doripenem and imipenem in the active site. Schroder et al. (2016)
Class C β-lactamases ADC-30 Sulbactam resistance 21/98 of ADCs isolated from multidrug-resistant Ab were ADC-30; overexpression of ADC-30 contributes to sulbactam resistance in Ab. Kuo et al. (2015)
ADC-162 Not determined ADC-30 with A220E, which is a substitution in the Ω loop region.
ADC-56 Cefepime resistance ADC-30 with an R148Q substitution. Molecular modeling demonstrated that the R148Q substitution in ADC-56 disrupts hydrogen bonds with Q267, E272, and I291 providing the H-10 helix more flexibility, likely allowing for better binding and turnover of cefepime. Tian et al. (2011)
ADC-33 Increased hydrolysis of ceftazidime, cefepime, and aztreonam In ADC-33, an alanine insertion allowed for the hydrolysis of ceftazidime, cefepime, and aztreonam at high levels. Rodriguez-Martinez et al. (2010)
ADC-219 Not determined ADC-33 with G222D, which is a substitution in the Ω loop region.
ADC-212 Not determined ADC-25 with A200D/P219L and an alanine insertion between P219L and A220. In ADC-212, the P219L followed by an alanine insertion might confer the same phenotype as in ADC-33. Rodriguez-Martinez et al. (2010)
Open in a new tab

Table 4.

Comparison of RMDs ability to detect carbapenemase genes found in this study.a

Platform OXA-23 OXA-24/40 OXA-58 OXA-72 OXA-82 OXA-172
Verigene BC-GN Yes Yes Yes Yesb No No
BioFire Film Array No No No No No No
Xpert® Carba-R Assay No No No No No No
Acuitas AMR Gene Panel No No No No No No
ePlex BCID-GN Panel Yes No No No No No
Check-points CT 103XL yes Yes Yes Yesb No No
Open in a new tab
a

Data as determined from platform's product literature.

b

Predicted to be detected based on in silico analysis, would call it OXA-24/40.

OXA-23 has been shown to be a major driver of carbapenem resistance in Ab, and OXA-24/40, an enzyme similar to OXA-23 in structure and specificity, is also extensively found. Both are acquired high affinity carbapenemases that have a common structural feature thought to be primarily responsible for this property. This structural feature is a hydrophobic bridge of two residues that stretches across the top of the active site (Table 3) (Kaitany et al., 2013; Santillana et al., 2007; Schneider et al., 2011; Smith et al., 2013; Stewart et al., 2019). It is important to note that both of these acquired carbapenemase genes are found on highly transmissible mobile genetic elements, this is particularly worrisome from an infection control standpoint, because not only can horizontal transmission of these common resistance elements occur between Acinetobacter strains and plasmids, but also interspecies plasmid transfer can occur (Grosso et al., 2012).

Of note, we have identified OXA variants in this collection with substitutions that expand their substrate profile. OXA-82 is one such variant, a L167V substitution in OXA-66 greatly enhances the hydrolytic efficiency of that enzyme toward carbapenems (Table 3) (Zander et al., 2013; Mitchell and Leonard, 2014). In most isolates, an acquired bla OXA carbapenemase allele was found in addition to the intrinsic or chromosomal bla OXA allele. However, in 18 isolates it appears that the intrinsic bla OXA-66 was converted by mutation to bla OXA-82. Another such variant in this collection was OXA-172, found in 2 ST1088 isolates. It also appears to have evolved from bla OXA-66, as no other intrinsic bla OXA was found, and it differs from OXA-66 by 2 substitutions, I129V and W222L. It has been shown that these substitutions result in tighter binding of the enzyme to doripenem and imipenem. In fact, OXA-172 displayed carbapenem K S values comparable to those of OXA-23 and OXA-24/40 (Schroder et al., 2016). ISAba1 was found upstream of bla OXA-82 and bla OXA-172 (both intrinsic bla OXAs), as previously reported in other isolates; this is of utmost importance, as the presence of this insertion element is necessary for a clinically CR phenotype, because these bla OXAs are weak carbapenemases and the IS element provides a strong promoter for overexpression (Zander et al., 2013; Zander et al., 2012). Also of note, the wild-type OXA-66 does not display the carbapenemase activity of its point mutation derivative OXA-82 (Zander et al., 2013). Lastly, OXA-72, which is OXA-24/40 with a G224D substitution, was present in 6 isolates. OXA-72 retains its carbapenemase activity and has been associated with numerous outbreaks (Barnaud et al., 2010; Franolic-Kukina et al., 2011; Lee et al., 2009; Lu et al., 2009).

It is an extremely troubling finding that 20% of isolates contained bla OXA-82 and bla OXA-172 carbapenemase genes, as currently available RMD platforms do not assay for these resistance determinants, nor do they detect the presence of ISAba1insertion elements upstream of the genes. It is important to keep in mind that without the IS element upstream, these bla OXAs, including bla OXA-23, do not confer carbapenem resistance. Even WGS can miss ISAba1-associated bla genes due to the ISAba1insertion sequences being present in multiple locations of the chromosome and plasmids, leading to misassembles and fragmented contigs when only using short Illumina reads. It has been our experience that besides closing genomes by inclusion of long reads, standard PCR amplifications are needed to accurately determine the ISAba1 positions relative to a gene of interest, such as bla OXA-82 and bla OXA-172 (Zander et al., 2013; Zander et al., 2012).

Table 4 compares the ability of various RMD platforms to detect the carbapenemase genes found in this collection of Ab isolates. As can be seen, none of the currently available platforms are able to detect bla OXA-82 and bla OXA-172. BioFire Film Array, Xpert® Carba-R Assay, and Acuitas AMR Gene Panel do not even detect bla OXA-23, which was by far the most commonly found OXA carbapenemase allele (80% of isolates).

ADCs are chromosomally encoded class C β-lactamases, found in Ab and other Acinetobacter spp., that are responsible for resistance to penicillins, cephalosporins, and BL/BLI combinations (Hujer et al., 2005). Being among the first laboratories to recognize the importance of this β-lactamase, our early work showed that ADC-7 β-lactamase demonstrates a remarkably high turnover rate for first-generation cephalosporins and relatively low affinity for the commercially available BLIs (Hujer et al., 2005).

The ADC allele most commonly found in this collection was bla ADC-212 (n = 25/98 isolates). It encoded an ADC-25-like β-lactamase with the following substitutions: A200D, P219L, and an Ala219a insertion between P219L and A220 (SANC numbering) (Table 2). ADC-33 (ADC-30-like, with a P213R substitution and the same insertion of an Ala residue inside the Ω loop) hydrolyzes ceftazidime, cefepime, and aztreonam, but not carbapenems (Rodriguez-Martinez et al., 2010). We speculate that for ADC-212, the Ala219a (between P219L and A220) might confer an extended-spectrum resistance phenotype similar to ADC-33 (Tables 2 and 3). In efforts to understand the importance of these substitutions in the larger context of structure-activity relationships, we generated preliminary data that suggests the alanine insertion between P219L and A220 in the Ω loop increases ceftazidime MICs from 16 mg/L to greater than 512 mg/L (unpublished data).

Other studies of ADC variants found within this collection demonstrate that subtle changes in the active site can lead to alterations in substrate turnover. ADC-30 was shown to contribute to sulbactam resistance when overexpressed in Ab (Kuo et al., 2015). Within our collection, bla ADC-30 (n = 21/98 isolates) and bla ADC-162 (n = 21/98 isolates) were also frequently found. ADC-162 is ADC-30 with an A220E substitution in the Ω loop region. Additionally, ADC-56 present in some of our clinical isolates, is a variant of ADC-30 containing a single mutation at R148Q that confers the ability to hydrolyze cefepime (Table 3) (Tian et al., 2011). Even more worrisome is ADC-68, an ADC that has gained the ability to hydrolyze carbapenems. ADC-68 was not identified in this study, but is worthy of mention given its carbapenemase activity (Jeon et al., 2014).

In conclusion, we believe that bla OXA-82 and bla OXA-172 are currently underappreciated as causative agents of, and contributors to, carbapenem resistance in Ab, as they were present in 20% of the CR Ab. Additionally, we anticipate that focusing our efforts of inhibition on targeting the various combinations of β-lactamases found in currently circulating, clinical isolates of Ab will enable us to truly assess whether newly synthesized inhibitors will be effective in the clinic. Our innovative approach considers all the β-lactamases occurring in a single organism based on the WGS combinations observed in this contemporary group of isolates from the US. Inhibitors need to effectively inhibit all of these β-lactamases simultaneously, and it is critical to counter bacterial resistance caused by the expansion and expression of multiple β-lactamases. We believe this a possibility, and that the impact of these studies may have broader implications for other bacterial pathogens.

Funding

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to R.A.B. under Award Numbers R01AI100560, R01AI063517, and R01AI072219, and has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases of the NIH, Department of Health and Human Services under Award Number U19AI110819. P.N.R. is supported by funding from the U.S. Department of Veterans Affairs I01 BX001725, IK6BX004470 and NIH awards R21AI142489 and R01AI072219. This study was also supported in part by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, Award Number 1I01BX001974 to R.A.B. from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development, and the Geriatric Research Education and Clinical Center VISN 10. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of Veterans Affairs.

Authors Contribution

Andrea M. Hujer: Writing-original and final draft presentations; data analysis; and conceptualization. Kristine M. Hujer: Reviewing and editing of manuscript; data review. David A. Leonard: Conceptualization; reviewing and editing of manuscript. Rachel A. Powers: Conceptualization; reviewing and editing of manuscript. Bradley J. Wallar: Conceptualization; reviewing and editing of manuscript. Andrew R. Mack: Data analysis; reviewing and editing of manuscript. Magdalena A. Taracila: Data analysis. Philip N. Rather: reviewing and editing of manuscript. Paul G. Higgins: Conceptualization; reviewing and editing of manuscript. Fabio Prati: Reviewing and editing of manuscript. Emilia Caselli: Reviewing and editing of manuscript. Steven H. Marshall: Data acquisition, curation, and analysis. Thomas Clarke: Data acquisition, curation, and analysis. Christopher Greco: Data acquisition, curation, and analysis. Pratap Venepally: Data acquisition, curation, and analysis. Lauren Brinkac: Data acquisition, curation, and analysis. Barry N. Kreiswirth: Reviewing and editing of manuscript. Derrick E. Fouts: Supervision; data acquisition and curation; reviewing and editing of manuscript. Robert A. Bonomo: Conceptualization; supervision; reviewing and editing of manuscript.

References

  1. http://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
  2. Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Investig Drugs. 2018;27:193–197. doi: 10.1080/13543784.2018.1426745. [DOI] [PubMed] [Google Scholar]
  3. Durand-Reville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H. ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104. doi: 10.1038/nmicrobiol.2017.104. [DOI] [PubMed] [Google Scholar]
  4. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2018;62 doi: 10.1128/AAC.01454-17. e01454-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Mushtaq S, Vickers A, Woodford N, Livermore DM. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D beta-lactamases. J Antimicrob Chemother. 2017;72:1688–1695. doi: 10.1093/jac/dkx035. [DOI] [PubMed] [Google Scholar]
  6. Papp-Wallace KM, Nguyen NQ, Jacobs MR, Bethel CR, Barnes MD, Kumar V. Strategic approaches to overcome resistance against gram-negative pathogens using beta-Lactamase Inhibitors and beta-Lactam Enhancers: activity of three novel diazabicyclooctanes WCK 5153, zidebactam (WCK 5107), and WCK 4234. J Med Chem. 2018;61:4067–4086. doi: 10.1021/acs.jmedchem.8b00091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Shapiro AB, Gao N, Jahic H, Carter NM, Chen A, Miller AA. Reversibility of covalent, broad-spectrum serine beta-Lactamase inhibition by the Diazabicyclooctenone ETX2514. ACS Infect Dis. 2017;3:833–844. doi: 10.1021/acsinfecdis.7b00113. [DOI] [PubMed] [Google Scholar]
  8. Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567–588. doi: 10.1007/s40265-016-0545-8. [DOI] [PubMed] [Google Scholar]
  9. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother. 2000;44:1556–1561. doi: 10.1128/aac.44.6.1556-1561.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother. 2000;44:196–199. doi: 10.1128/aac.44.1.196-199.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother. 2005;49:2941–2948. doi: 10.1128/AAC.49.7.2941-2948.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics to identify susceptibility and resistance to carbapenems against Acinetobacter spp. in PRIMERS III. J Clin Microbiol. 2017;55:134–144. doi: 10.1128/JCM.01524-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:1409–1417. doi: 10.1164/rccm.201102-0349OC. [DOI] [PubMed] [Google Scholar]
  14. Cilloniz C, Dominedo C, Torres A. Multidrug resistant gram-negative bacteria in community-acquired Pneumonia. Crit Care. 2019;23:79. doi: 10.1186/s13054-019-2371-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020;20:697–706. doi: 10.1016/S1473-3099(20)30200-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mohd Sazlly Lim S, Zainal Abidin A, Liew SM, Roberts JA, Sime FB. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis. J Infect. 2019;79:593–600. doi: 10.1016/j.jinf.2019.09.012. [DOI] [PubMed] [Google Scholar]
  17. Ozgur ES, Horasan ES, Karaca K, Ersoz G, Nayci Atis S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control. 2014;42:206–208. doi: 10.1016/j.ajic.2013.09.003. [DOI] [PubMed] [Google Scholar]
  18. Serota DP, Sexton ME, Kraft CS, Palacio F. Severe community-acquired pneumonia due to Acinetobacter baumannii in North America: case report and review of the literature. Open Forum Infect Dis. 2018;5:ofy044. doi: 10.1093/ofid/ofy044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30:409–447. doi: 10.1128/CMR.00058-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2006;50:4114–4123. doi: 10.1128/AAC.00778-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Perez F, Endimiani A, Ray AJ, Decker BK, Wallace CJ, Hujer KM. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother. 2010;65:1807–1818. doi: 10.1093/jac/dkq191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–477. doi: 10.1089/cmb.2012.0021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 2016;44:6614–6624. doi: 10.1093/nar/gkw569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Segal H, Garny S, Elisha BG. Is ISAba-1 customized for Acinetobacter? FEMS Microbiol Lett. 2005;243:425–429. doi: 10.1016/j.femsle.2005.01.005. [DOI] [PubMed] [Google Scholar]
  25. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27:351–353. doi: 10.1016/j.ijantimicag.2006.01.004. [DOI] [PubMed] [Google Scholar]
  26. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodriguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005;43:4382–4390. doi: 10.1128/JCM.43.9.4382-4390.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS One. 2010;5:e10034. doi: 10.1371/journal.pone.0010034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zander E, Chmielarczyk A, Heczko P, Seifert H, Higgins PG. Conversion of OXA-66 into OXA-82 in clinical Acinetobacter baumannii isolates and association with altered carbapenem susceptibility. J Antimicrob Chemother. 2013;68:308–311. doi: 10.1093/jac/dks382. [DOI] [PubMed] [Google Scholar]
  29. Mitchell JM, Leonard DA. Common clinical substitutions enhance the carbapenemase activity of OXA-51-like class D beta-lactamases from Acinetobacter spp. Antimicrob Agents Chemother. 2014;58:7015–7016. doi: 10.1128/AAC.03651-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schroder EC, Klamer ZL, Saral A, Sugg KA, June CM, Wymore T. Clinical variants of the native class D beta-lactamase of Acinetobacter baumannii pose an emerging threat through increased hydrolytic activity against carbapenems. Antimicrob Agents Chemother. 2016;60:6155–6164. doi: 10.1128/AAC.01277-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Poirel L, Marque S, Heritier C, Segonds C, Chabanon G, Nordmann P. OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49:202–208. doi: 10.1128/AAC.49.1.202-208.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kuo SC, Lee YT, Yang Lauderdale TL, Huang WC, Chuang MF, Chen CP. Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front Microbiol. 2015;6:231. doi: 10.3389/fmicb.2015.00231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:3484–3488. doi: 10.1128/AAC.00050-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mack AR, Barnes MD, Taracila MA, Hujer AM, Hujer KM, Cabot G. A standard numbering scheme for class C beta-lactamases. Antimicrob Agents Chemother. 2020;64 doi: 10.1128/AAC.01841-19. e01841-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Adams MD, Wright MS, Karichu JK, Venepally P, Fouts DE, Chan AP. Rapid Replacement of Acinetobacter baumannii Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. mBio. 2019;10 doi: 10.1128/mBio.00356-19. e00963-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wright MS, Haft DH, Harkins DM, Perez F, Hujer KM, Bajaksouzian S. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. mBio. 2014;5 doi: 10.1128/mBio.00963-13. e00963-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wright MS, Iovleva A, Jacobs MR, Bonomo RA, Adams MD. Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med. 2016;8:26. doi: 10.1186/s13073-016-0279-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kaitany KC, Klinger NV, June CM, Ramey ME, Bonomo RA, Powers RA. Structures of the class D Carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins, and aztreonam. Antimicrob Agents Chemother. 2013;57:4848–4855. doi: 10.1128/AAC.00762-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Santillana E, Beceiro A, Bou G, Romero A. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci U S A. 2007;104:5354–5359. doi: 10.1073/pnas.0607557104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schneider KD, Ortega CJ, Renck NA, Bonomo RA, Powers RA, Leonard DA. Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J Mol Biol. 2011;406:583–594. doi: 10.1016/j.jmb.2010.12.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Smith CA, Antunes NT, Stewart NK, Toth M, Kumarasiri M, Chang M. Structural basis for carbapenemase activity of the OXA-23 beta-lactamase from Acinetobacter baumannii. Chem Biol. 2013;20:1107–1115. doi: 10.1016/j.chembiol.2013.07.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Stewart NK, Smith CA, Antunes NT, Toth M, Vakulenko SB. Role of the hydrophobic bridge in the carbapenemase activity of class D beta-Lactamases. Antimicrob Agents Chemother. 2019;63 doi: 10.1128/AAC.02191-18. e02191-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Grosso F, Quinteira S, Poirel L, Novais A, Peixe L. Role of common blaOXA-24/OXA-40-carrying platforms and plasmids in the spread of OXA-24/OXA-40 among Acinetobacter species clinical isolates. Antimicrob Agents Chemother. 2012;56:3969–3972. doi: 10.1128/AAC.06255-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Zander E, Nemec A, Seifert H, Higgins PG. Association between beta-lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of Acinetobacter baumannii isolates. J Clin Microbiol. 2012;50:1900–1904. doi: 10.1128/JCM.06462-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Barnaud G, Zihoune N, Ricard JD, Hippeaux MC, Eveillard M, Dreyfuss D. Two sequential outbreaks caused by multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 or OXA-72 oxacillinase in an intensive care unit in France. J Hosp Infect. 2010;76:358–360. doi: 10.1016/j.jhin.2010.05.026. [DOI] [PubMed] [Google Scholar]
  46. Franolic-Kukina I, Bedenic B, Budimir A, Herljevic Z, Vranes J, Higgins PG. Clonal spread of carbapenem-resistant OXA-72-positive Acinetobacter baumannii in a Croatian university hospital. Int J Infect Dis. 2011;15:e706–e709. doi: 10.1016/j.ijid.2011.05.016. [DOI] [PubMed] [Google Scholar]
  47. Lee K, Kim MN, Choi TY, Cho SE, Lee S, Whang DH. Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int J Antimicrob Agents. 2009;33:520–524. doi: 10.1016/j.ijantimicag.2008.10.009. [DOI] [PubMed] [Google Scholar]
  48. Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother. 2009;63:641–647. doi: 10.1093/jac/dkn553. [DOI] [PubMed] [Google Scholar]
  49. Tian GB, Adams-Haduch JM, Taracila M, Bonomo RA, Wang HN, Doi Y. Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. Antimicrob Agents Chemother. 2011;55:4922–4925. doi: 10.1128/AAC.00704-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Jeon JH, Hong MK, Lee JH, Lee JJ, Park KS, Karim AM. Structure of ADC-68, a novel carbapenem-hydrolyzing class C extended-spectrum beta-lactamase isolated from Acinetobacter baumannii. Acta Crystallogr D Biol Crystallogr. 2014;70:2924–2936. doi: 10.1107/S1399004714019543. [DOI] [PubMed] [Google Scholar]
  51. De Luca F, Benvenuti M, Carboni F, Pozzi C, Rossolini GM, Mangani S. Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D beta-lactamase OXA-10 by rational protein design. Proc Natl Acad Sci U S A. 2011;108:18424–18429. doi: 10.1073/pnas.1110530108. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Diagnostic Microbiology and Infectious Disease are provided here courtesy of Elsevier

RESOURCES